Patents by Inventor Mark D. Scott
Mark D. Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11007221Abstract: This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Acellular-based preparations and processes for achieving therapy are also provided.Type: GrantFiled: December 13, 2013Date of Patent: May 18, 2021Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20200147133Abstract: This disclosure relates to acellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one acellular pro-tolerogenic preparation and at least one acellular pro-inflammatory preparation are administered sequentially.Type: ApplicationFiled: January 14, 2020Publication date: May 14, 2020Inventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10561685Abstract: This disclosure relates to a cellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one a cellular pro-tolerogenic preparation and at least one a cellular pro-inflammatory preparation are administered sequentially.Type: GrantFiled: July 10, 2015Date of Patent: February 18, 2020Assignee: CANADIAN BLLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10188681Abstract: This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population. The non-proliferative allogeneic leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition with the latter leukocyte population. Cellular-based preparations and processes for achieving cellular therapy are also provided.Type: GrantFiled: July 12, 2013Date of Patent: January 29, 2019Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10039787Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses intended for the treatment/prevention of auto-immune diseases of such compositions are also provided.Type: GrantFiled: July 12, 2013Date of Patent: August 7, 2018Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10039786Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided.Type: GrantFiled: July 12, 2013Date of Patent: August 7, 2018Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 10039788Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.Type: GrantFiled: July 12, 2013Date of Patent: August 7, 2018Assignee: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20170173078Abstract: This disclosure relates to a cellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one a cellular pro-tolerogenic preparation and at least one a cellular pro-inflammatory preparation are administered sequentially.Type: ApplicationFiled: July 10, 2015Publication date: June 22, 2017Applicant: CANANDIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 9498496Abstract: This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.Type: GrantFiled: July 12, 2013Date of Patent: November 22, 2016Assignee: CANADIAN BLOOD CERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20160206655Abstract: This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Acellular-based preparations and processes for achieving therapy are also provided.Type: ApplicationFiled: December 13, 2013Publication date: July 21, 2016Applicant: CANADIAN BLOOD SERVICESInventors: Mark D. SCOTT, Duncheng WANG, Wendy M. TOYOFUKU
-
Publication number: 20150209387Abstract: This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population. The non-proliferative allogeneic leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition with the latter leukocyte population. Cellular-based preparations and processes for achieving cellular therapy are also provided.Type: ApplicationFiled: July 12, 2013Publication date: July 30, 2015Inventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20150202229Abstract: This invention relates to cellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population capable of proliferating. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.Type: ApplicationFiled: July 12, 2013Publication date: July 23, 2015Inventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20150196597Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.Type: ApplicationFiled: July 12, 2013Publication date: July 16, 2015Applicant: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20150174168Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided.Type: ApplicationFiled: July 12, 2013Publication date: June 25, 2015Applicant: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20150164948Abstract: This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses intended for the treatment/prevention of auto-immune diseases of such compositions are also provided.Type: ApplicationFiled: July 12, 2013Publication date: June 18, 2015Applicant: CANADIAN BLOOD SERVICESInventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Publication number: 20140017218Abstract: This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.Type: ApplicationFiled: July 12, 2013Publication date: January 16, 2014Inventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
-
Patent number: 8454934Abstract: A chelation structure and method of forming and using the chelation structure. The chelation structure has a backbone that includes a linear sequence of monomeric backbone units, at least one polymer side chain, and at least one chelator side chain. The side chains are each covalently coupled to the backbone at one of the monomeric backbone units by a bond that is independently biodegradable or non-biodegradable. The chelation structure is synthesized by Radical Addition Fragmentation Transfer (RAFT), Atom Transfer Radical Polymerization (ATRP), or Free Radical Polymerization (FRP). The chelation structure, individually or in combination with a shuttle chelator, may be introduced into a mammal to bind an amount of a substance in a mammal, the substance being at least one of a metal and heme. The chelation structure has a log stability constant exceeding that of the shuttle chelator for binding the substance within cells of the mammal.Type: GrantFiled: May 25, 2006Date of Patent: June 4, 2013Assignee: Canadian Blood ServicesInventors: Mark D. Scott, Jayachandran N. Kizhakkedathu
-
Patent number: 8067151Abstract: A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker molecule such that the linker molecule is covalently bonded to the platelet and the polymer is covalently attached to the linker molecule. The polymer of each polymerated chemical of each modified platelet is polyethylene glycol (PEG) or a PEG derivative. Forming each modified platelet does not include modifying the platelet membrane of each platelet with a glycan-modifying agent. The at least one modified platelet is stored in a temperature range below 0° C. After being stored, the at least one modified platelet may be introduced into a subject to treat a condition related to a reduced platelet function.Type: GrantFiled: July 14, 2008Date of Patent: November 29, 2011Assignee: Canadian Blood ServicesInventors: Elisabeth Maurer, Mark D. Scott, Nobu Kitamura
-
Patent number: 8007784Abstract: The present invention is directed to a non-immunogenic cellular composition comprising: a cell having a cell surface and antigenic determinants on the cell surface; an optional linker molecule covalently attached to the cell surface; and a hydrophilic, biocompatible, non-immunogenicity providing compound or polymer (e.g., polyethylene glycol or a derivative thereof) covalently attached to the linker molecule or directly to the cell. In one embodiment, the linker molecule is covalently attached directly to the antigenic determinant on the cell surface. In an alternate embodiment, the linker molecule may be covalently attached to a non-antigenic site on the cell surface, but will camouflage the antigenic determinant on the cell surface.Type: GrantFiled: June 1, 1999Date of Patent: August 30, 2011Assignee: Albany Medical CollegeInventors: Mark D. Scott, John W. Eaton
-
Patent number: 7964339Abstract: A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker molecule such that the linker molecule is covalently bonded to the platelet and the polymer is covalently attached to the linker molecule. The polymer of each polymerated chemical of each modified platelet is polyethylene glycol (PEG) or a PEG derivative. Forming each modified platelet does not include modifying the platelet membrane of each platelet with a glycan-modifying agent. The at least one modified platelet is stored in a temperature range below 20° C. for at least one hour. After being stored, the at least one modified platelet may be introduced into a mammal.Type: GrantFiled: February 9, 2007Date of Patent: June 21, 2011Assignee: Canadian Blood ServicesInventors: Mark D. Scott, Elisabeth Maurer